Kelun Founder Passes Board Chair to Current General Manager

Company Sichuan Kelun Pharmaceutical (SZSE 002422) Event Type Board chair transition (previously missed 18 Nov Chinese filing) Modality Not applicable Asset Not applicable (parent of Kelun-Biotech; sac-TMT licensed to Merck) Target Not applicable Disease Area Pharmaceutical group; oncology ADC exposure Summary Sichuan Kelun Pharmaceutical disclosed…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *